Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

(2020) Mikiya Ishihara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

(2020) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly-ICLC, a multi-functional immune modulator for treating cancer

(2020) Hussein Sultan et al.   SEMINARS IN IMMUNOLOGY

Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration

(2020) Hussein Sultan et al.   Journal for ImmunoTherapy of Cancer

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

(2019) Daisuke Muraoka et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

(2019) Elizabeth A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

(2019) Anna Pavlick et al.   Cancer Immunology Research

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

(2018) M E Rodríguez-Ruiz et al.   ANNALS OF ONCOLOGY

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

(2018) Brigitte Dreno et al.   LANCET ONCOLOGY

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

(2018) Yelena Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

(2017) Shikhar Mehrotra et al.   Journal of Hematology & Oncology

Vaccine adjuvants as potential cancer immunotherapeutics

(2016) Burcu Temizoz et al.   INTERNATIONAL IMMUNOLOGY

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Johan F Vansteenkiste et al.   LANCET ONCOLOGY

NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers

(2015) Yoko Oshima et al.   JOURNAL OF GASTROENTEROLOGY

Vaccine adjuvant uses of poly-IC and derivatives

(2014) Karen AO Martins et al.   Expert Review of Vaccines

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

(2013) Shinichi Kageyama et al.   Journal of Translational Medicine

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells

(2010) D. Muraoka et al.   JOURNAL OF IMMUNOLOGY

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

(2009) Masatoshi Aoki et al.   VACCINE